Wall Street Week
Welcome to the Wall Street Week newsletter, bringing you stories of capitalism about things you need to know, but even more things you need
View in browser
Bloomberg
by David Westin

Welcome to the Wall Street Week newsletter, bringing you stories of capitalism about things you need to know, but even more things you need to think about. I'm David Westin, and this week diplomat Richard Haass took us through the conflict between Israel and Iran, while Johnson & Johnson CEO Joaquin Duato took us into the the world of biotech innovation.  If you're not yet a subscriber, sign up here for this newsletter.

Uncertainty in the Middle East

This week the Middle East was thrust into turmoil when Israel launched an attack on Iran's nuclear projects and some of its top military leadership. Richard Haass served in a series of foreign policy positions in the White House and the State Department and went on to lead the Council on Foreign Relations for over 20 years. He told us that, at this point, we have more questions than answers, including about "what more Israel plans to do," with Iran having a "massive set of options."

Nor do we know what role, if any, the US played behind the scenes, though Haass says "based on my experience, if a US president tells an Israeli prime minister not to do something, Israel usually holds back."

Haass isn’t as concerned about the price of oil at this point, noting that "oil prices are relatively modest, historically" and if they "stabilize in the low $70s, that's manageable." Although this "adds another layer of uncertainty to global economics overall,” for Haass "the bigger concerns are still 'Made in America.'"

"Global leaders and central bankers no longer operate with a stable, predictable sense of what the US will do,” he said. “That alone causes them to hedge, and that has consequences."

‘Golden era of medical innovation’

Some industries are already deep into their use of artificial intelligence to improve what they do — and even to let them do things that would have been imaginable just a few years ago. The world of biotechnology is moving ahead rapidly to adopt and adapt AI as it searches for new drugs and therapies to address the world's ills.

Zara Muradali heads the life sciences industry practice at Grant Thornton and focused on "a lot of venture capital funds that are really investing in the biotech space in the seed and early stages." In particular, she's "seeing collaboration agreements with the companies that are AI first."

One of the leading investors in biotech research and development is Johnson & Johnson, which has invested about $50 billion in research and development since January 2024. Its Chair and CEO, Joaquin Duato, says there's never been a more exciting time to be working in the field because of what's being discovered.

More from Wall Street Week

More from Bloomberg

  • Markets Daily has what’s happening in stocks, bonds, currencies and commodities right now
  • Supply Lines follows the trade wars, tariff threats and logistics shocks that are upending business and spreading volatility
  • Get the Bloomberg Weekend newsletter for big ideas and open questions in the fascinating places where finance, life and culture meet
  • Spend your Sunday thinking about what's ahead with The Forecast newsletter

Explore all Bloomberg newsletters.

Follow Us
You received this message because you are subscribed to Bloomberg's Wall Street Week newsletter. If a friend forwarded you this message, sign up here to get it in your inbox.
Unsubscribe
Bloomberg.com
Contact Us
Bloomberg L.P.
731 Lexington Avenue,
New York, NY 10022
Ads Powered By Liveintent Ad Choices